Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06439277 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

StatusRecruiting
PhasePhase 3
Started2024-06-03
View on ClinicalTrials.gov ↗
The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits. Participants who have completed the primary 72-week GPIX study and have been off treatment for no more than 12 weeks (including the 4-week safety follow-up period), will have the opportunity to receive an additional 156 weeks of treatment with tirzepatide as well as continuing the lifestyle intervention.

Amendment record

Amended 34 times since 2024-05-28; most recent filed 2026-08-06. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-31.

2026-08-06
Amendment Study Status, Contacts/Locations v34
2026-07-17
Amendment Study Status, Contacts/Locations v33
2026-07-03
Amendment Study Status, Contacts/Locations v32
2026-06-17
Amendment Study Status, Contacts/Locations v31
2026-06-01
Amendment Study Status, Contacts/Locations v30
2026-05-18
Amendment Study Status v29
2026-05-11
Amendment Study Status, Contacts/Locations v28
2026-04-17
Amendment Study Status, Contacts/Locations v27
2026-03-22
Amendment Study Status, Contacts/Locations v26
2026-02-27
Amendment Study Status, Contacts/Locations v25
2026-02-09
Amendment Study Status, Contacts/Locations v24
2026-01-20
Amendment Study Status, Contacts/Locations v23
2026-01-12
Amendment Study Status, Contacts/Locations v22
2025-12-08
Amendment Study Status, Contacts/Locations v21
2025-11-21
Amendment Study Status, Contacts/Locations v20
2025-11-05
Amendment Study Status, Contacts/Locations v19
2025-10-08
Amendment Study Status, Contacts/Locations v18
2025-09-24
Amendment Study Status, Contacts/Locations v17
2025-08-26
Amendment Study Status, Contacts/Locations v16
2025-08-15
Amendment Study Status, Study Description, Contacts/Locations v15
2025-07-22
Amendment Study Status, Contacts/Locations v14
2025-07-07
Amendment Study Status, Contacts/Locations v13
2025-06-24
Amendment Study Status, Contacts/Locations v12
2025-05-25
Amendment Study Status, Contacts/Locations, IPDSharing v11
2025-04-17
Amendment Study Status, Contacts/Locations v10
2025-02-25
Amendment Study Status, Contacts/Locations v9
2025-01-20
Amendment Study Status, Contacts/Locations v8
2024-12-06
Amendment Study Status, Contacts/Locations v7
2024-10-08
Amendment Study Status, Contacts/Locations v6
2024-09-12
Amendment Study Status, Contacts/Locations v5
2024-08-25
Amendment Study Status, Contacts/Locations v4
2024-07-23
Amendment Study Status, Contacts/Locations v3
2024-07-21
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
2024-06-21
Amendment Study Status, References v1
2024-05-28
Original filing
Trial Details
NCT Number NCT06439277
Lead Sponsor Eli Lilly and Company
Conditions Obesity, Weight Gain
Enrollment 300 participants
Start Date 2024-06-03
Primary Completion 2027-10 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-09-04